Circulating tumour DNA in patients with melanoma receiving targeted therapy
Menée à partir d'échantillons plasmatiques prélevés sur 345 patients atteints d'un mélanome de stade avancé traité par le dabrafénib en combinaison ou non avec le tramétinib dans le cadre d'essais cliniques de phase II ou III (âge : 18 ans ou plus), cette étude évalue l'association entre la concentration en ADN tumoral circulant avec mutation V600 du gène BRAF avant ou pendant le traitement (semaine 4) et la survie sans progression ainsi que la survie globale
The prognosis of patients with metastatic melanoma has improved considerably with the introduction of targeted therapy and immune checkpoint inhibition. Nevertheless, there is still a need for reliable biomarkers that can help to identify patients at high risk of treatment failure and to allow early detection of progression during ongoing therapy. One promising biomarker in this context is circulating tumour DNA (ctDNA), which can be easily obtained from patients' blood. Concerning the relevance of ctDNA in estimating overall survival of patients with melanoma, a comprehensive overview can be found in a recently published meta-analysis and review by Gandini and colleagues. It is currently assumed that non-detectable ctDNA is a favourable prognostic parameter and ctDNA concentration assessed during targeted therapy or immune checkpoint inhibition seem to be suitable for monitoring treatment response.
The Lancet Oncology , commentaire, 2020